Reading AKBA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AKBA free→Reading AKBA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AKBA free→QuarterlyIQ Insights · AKBA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 7, 2026, Akebia Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026 and recent business highlights. A copy of the Company’s press release containing this information is furnished as Exhibit 99.1 to this Current Report on Form 8-K (“Report”) and is incorporated herein by reference. The information in this Report (including
Results of Operations and Financial Condition. On February 26, 2026, Akebia Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025 and recent business highlights related to the commercial launch of Vafseo® (vadadustat) as well as its pipeline. A copy of the Company’s press release containing this information is furnished as Exhibit 99.1 to this Current Report on Form 8-K (“Report”) and is incorpor…
Entry into a Material Definitive Agreement. On January 27, 2026, Akebia Therapeutics, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with BP THIRD AVENUE LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company will lease an aggregate of approximately 43,474 square feet, consisting of 28,518 square feet of office space (the “Office Premises”) and 14,956 square feet of laboratory space (the “Lab Premises”) located at the building commonly kno…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of Registrant. The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. CEO Executive Severance Agreement On January 28, 2026 (the “Effective Date”), the Company entered into an amended and restated executive severance agreement (the “Amended CEO Executive Severance Agreement”) with the Company’s President and Chief Executive Officer, John P. Butler. The Amended CEO Executive Severance Agreement was approved by the Boa…
Results of Operations and Financial Condition. On January 12, 2026, Akebia Therapeutics, Inc. (the “Company”) issued a press release announcing key corporate updates associated with its Vafseo® (vadadustat) commercial business and providing an outlook on upcoming milestones, including for its next anticipated growth driver, the Company’s mid-stage rare kidney disease pipeline. The Company also provided an overview of expected fourth quarter 2025 Vafseo net product revenue. A copy of the Compa…
Entry into a Material Definitive Agreement. On November 28, 2025 (the “Closing Date”), Akebia Therapeutics, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Agreement”) with Q32 Bio Inc. and Q32 Bio Operations Inc. (together, “Q32”), pursuant to which Q32 sold and assigned to the Company, and the Company purchased and assumed from Q32, substantially all assets and liabilities of Q32 and its affiliates related to the research, development, manufacture, and commercialization…
Regulation FD Disclosure. On December 1, 2025, the Company issued a press release announcing the acquisition of a clinical-stage development candidate and the establishment of its rare kidney disease pipeline comprised of two core product candidates: ADX-097 (now referred to as AKB-097), a complement inhibitor, and praliciguat, a soluble guanylate cyclase stimulator. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by…
Entry into a Material Definitive Agreement. As previously disclosed, on May 24, 2023, Akebia Therapeutics, Inc. (the “Company”) and MEDICE Arzneimittel Putter GmbH & Co. KG (“Medice”) entered into a License Agreement (the “License Agreement”) pursuant to which the Company granted to Medice an exclusive license to develop and commercialize Vafseo for the treatment of anemia in patients with chronic kidney disease in Europe and certain other countries. On November 12, 2025, the Company and Medi…
Results of Operations and Financial Condition. On November 10, 2025, Akebia Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025 and recent business highlights. A copy of the Company’s press release containing this information is furnished as Exhibit 99.1 to this Current Report on Form 8-K (“Report”) and is incorporated herein by reference. The information in this Report (including
Results of Operations and Financial Condition. On August 7, 2025, Akebia Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025 and recent business highlights. A copy of the Company’s press release containing this information is furnished as Exhibit 99.1 to this Current Report on Form 8-K (“Report”) and is incorporated herein by reference. The information in this Report (including
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Akebia Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 10, 2025 (the “Annual Meeting”). The Company’s stockholders approved an amendment to the Company’s 2023 Stock Incentive Plan (the “2023 Plan”) to increase the number of shares of common stock available for issuance thereunder by 18,900,000 shares and to make c…
Results of Operations and Financial Condition. On May 8, 2025, Akebia Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025 and recent business highlights. A copy of the Company’s press release containing this information is furnished as Exhibit 99.1 to this Current Report on Form 8-K (“Report”) and is incorporated herein by reference. The information in this Report (including
Other Events. On March 19, 2025, the Company issued a press release (the “Press Release”) announcing the pricing of the Offering. A copy of the Press Release has been filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements of the Company that involve substantial risks and uncertainties. All statements, other than statements of histo…
Entry into a Material Definitive Agreement. On March 19, 2025, Akebia Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 25,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stoc…
Results of Operations and Financial Condition. On March 13, 2025, Akebia Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024 and commenting on certain business updates. A copy of the Company’s press release containing this information is furnished as Exhibit 99.1 to this Current Report on Form 8-K (“Report”) and is incorporated herein by reference. The information in this Report (including
Entry into a Material Agreement. On February 3, 2025, Akebia Therapeutics, Inc. (the “Company”) and Kreos Capital VII (UK) Limited (the “Lender Representative”) entered into the Second Amendment to the Agreement for the Provision of a Loan Facility (the “Second Amendment”), which amends certain provisions of the Agreement for the Provision of a Loan Facility, dated January 29, 2024 (the “Original Loan Agreement”, and as amended by that certain First Amendment to Agreement for the Provision of…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in
Unregistered Sales of Equity Securities. On February 3, 2025, in connection with the drawdown of the Extended Tranche C Loan, in accordance with the previously disclosed warrant agreement, dated as of January 29, 2024, between the Company and Kreos Capital VII Aggregator SCSp, an affiliate of the Lender Representative (the “Warrant Holder”), the Company issued a warrant to the Warrant Holder to purchase 1,153,846 shares of the Company’s common stock, at an exercise price per share of $1.30 (s…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.